A detailed history of Lion Point Capital, LP transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 340,761 shares of MCRB stock, worth $245,347. This represents 0.17% of its overall portfolio holdings.

Number of Shares
340,761
Previous 340,761 -0.0%
Holding current value
$245,347
Previous $477,000 45.07%
% of portfolio
0.17%
Previous 0.28%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.93 - $2.15 $326,469 - $754,740
-351,042 Reduced 50.74%
340,761 $477,000
Q2 2023

Aug 14, 2023

BUY
$4.67 - $6.55 $443,650 - $622,250
95,000 Added 15.92%
691,803 $3.31 Million
Q4 2022

Feb 14, 2023

SELL
$5.09 - $9.05 $152,700 - $271,500
-30,000 Reduced 4.79%
596,803 $3.34 Million
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $507,500 - $1.04 Million
145,000 Added 30.1%
626,803 $3.23 Million
Q3 2021

Nov 15, 2021

BUY
$5.46 - $22.6 $2.63 Million - $10.9 Million
481,803 New
481,803 $3.35 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.